Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6611-6619

  Perilli, Lisa ^a   Vicentini, Caterina ^c   Agostini, Marco ^a,d   Pizzini, Silvia ^a   Pizzi, Marco ^a   D'Angelo, Edoardo ^c   Bortoluzzi, Stefania ^a   Mandruzzato, Susanna ^a,b   Mammano, Enzo ^a   Rugge, Massimo ^a   Nitti, Donato ^a   Scarpa, Aldo ^c   Fassan, Matteo ^c   Zanovello, Paola ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Fondazione Istituto di Ricerca Pediatrica Città della Speranza   (Italy)

Author keywords

Biomarkers; Colon cancer; miR 182; Plasma

Indexed keywords

MICRORNA 182; TUMOR MARKER; ENTPD5 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; MICRORNA; MIRN182 MICRORNA, HUMAN; ONCOPROTEIN;

AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CARCINOGENESIS; COLON MUCOSA; COLON POLYP; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENTPD5 GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IRRITABLE COLON; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; OVERALL SURVIVAL; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; UPREGULATION; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; COLORECTAL TUMOR; DISEASE COURSE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; PATHOLOGY;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEK293 CELLS; HUMANS; MALE; MICRORNAS; ONCOGENE PROTEINS; PYROPHOSPHATASES; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84907064971     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2245     Document Type: Article

References (34)

1. Siegel R, Desantis C and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-117.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N. Colorectal cancer. Lancet. 2010; 375(9719):1030-1047.
3. Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D and Shapiro JD. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther. 2013; 13(5):597-611.
4. Markowitz SD and Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009; 361(25):2449-2460.
5. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
6. Valeri N, Croce CM and Fabbri M. Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics. 2009; 6(4):195-204.
7. Lovat F, Valeri N and Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011; 38(6):724-733.
8. Schetter AJ and Harris CC. Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol. 2011; 38(6):734-742.
9. Fassan M, Croce CM and Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol. 2011; 17(48):5231-5239.
10. Fassan M and Baffa R. MicroRNAs and targeted therapy: small molecules of unlimited potentials. Curr Opin Genet Dev. 2013; 23(1):75-77.
11. Schwarzenbach H, Nishida N, Calin GA and Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-156.
12. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hernando E and Wei JJ. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012; 228(2):204-215.
13. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009; 106(6):1814-1819.
14. Wang J, Li J, Shen J, Wang C, Yang L and Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012; 12:227.
15. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X and Tang H. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J. 2012; 279(7):1252-1260.
16. Sun Y, Fang R, Li C, Li L, Li F, Ye X and Chen H. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun. 2010; 396(2):501-507.
17. Yang WB, Chen PH, Hsu Ts, Fu TF, Su WC, Liaw H, Chang WC and Hung JJ. Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget. 2014; 5(3):740-753.
18. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN and Steer CJ. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009; 9:401.
19. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-1381.
20. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-436.
21. Rapti SM, Kontos CK, Papadopoulos IN and Scorilas A. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med. 2014.
22. Liu H, Du L, Wen Z, Yang Y, Li J, Wang L, Zhang X, Liu Y, Dong Z, Li W, Zheng G and Wang C. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis. 2013; 28(5):697-703.
23. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S and Zanovello P. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 2013; 14:589.
24. Fassan M, Baffa R and Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013; 27(2):159-169.
25. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010; 70(1):367-377.
26. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010; 126(5):1166-1176.
27. Amodeo V, Bazan V, Fanale D, Insalaco L, Caruso S, Cicero G, Bronte G, Rolfo C, Santini D and Russo A. Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? Expert Opin Ther Targets. 2013; 17(11):1249-1261.
28. Wang YQ, Guo RD, Guo RM, Sheng W and Yin LR. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem. 2013; 114(7):1464-1473.
29. Wang M, Wang Y, Zang W, Wang H, Chu H, Li P, Li M, Zhang G and Zhao G. Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. Tumour Biol. 2014; 35(1):39-46.
30. Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M and Ostrowski J. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics. 2010.
31. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW and Wang X. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell. 2010; 143(5):711-724.
32. MacCarthy CM and Notario V. The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family. Int J Oncol. 2013; 43(4):1244-1252.
33. Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L, Huang D, Tan C, Sheng W and Du X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398.
34. Giraldez MD, Lozano JJ, Ramirez G, Hijona E, Bujanda L, Castells A and Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2012; 11(6):681-688 e683.